Skip to main contentSkip to navigationSkip to search

Press releases and news

2021

Change in number of shares and votes in Camurus

Braeburn receives new Complete Response Letter for Brixadi in the US

The European Medicines Agency accepts application to extend the Buvidal indication to include treatment of chronic pain

Camurus announces dosing initiated in Phase 3 study of CAM2029 in patients with neuroendocrine tumors

Camurus’ Interim Report Third Quarter 2021

Camurus’ Nomination Committee appointed for the Annual General Meeting 2022

Camurus appoints Jon U. Garay Alonso as Chief Financial Officer

Change in number of shares and votes in Camurus

FDA grants Orphan Drug Designation in the US for CAM2029 for the treatment of polycystic liver disease

Camurus’ Chief Financial Officer (CFO) will leave the company

Change in number of shares and votes in Camurus

Camurus’ Interim Report Second Quarter 2021

Change in number of shares and votes in Camurus

Camurus announces PDUFA date for Brixadi for the treatment of opioid use disorder in the US

Camurus announces Braeburn resubmits New Drug Application for Brixadi™ in the US

Change in number of shares and votes in Camurus

Exercise of Camurus’ subscription warrant program 2018/2021

Camurus receives Carnegie Sustainability Award 2021

Camurus announces publication showing superior patient treatment satisfaction with Buvidal® weekly and monthly depot injections in opioid dependence

Resolutions at the annual general meeting 2021 in Camurus

Load more press releases

Subscribe

Get the latest news from Camurus

Subscribe to receive latest news from Camurus directly in your email inbox. 

Information types

By subscribing to news from Camurus, you agree to our privacy policy.

Thank you. You will get an e-mail message to activate your subscription.